DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,730
-410 (-2.26%)
Oct 30, 2025, 3:30 PM KST
-2.26%
Market Cap787.07B
Revenue (ttm)869.00B
Net Income (ttm)59.79B
Shares Out44.39M
EPS (ttm)1,344.35
PE Ratio13.19
Forward PE10.92
Dividend200.00 (1.10%)
Ex-Dividend DateDec 27, 2024
Volume293,686
Average Volume237,687
Open18,170
Previous Close18,140
Day's Range17,560 - 18,300
52-Week Range14,400 - 20,450
Beta0.34
RSI41.25
Earnings DateNov 14, 2025

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,211
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.

Financial Statements

News

There is no news available yet.